Skip to Content


Class: Thiazide-like Diuretics
VA Class: CV701
Chemical Name: 3-(Aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide
Molecular Formula: C16H16ClN3O3S
CAS Number: 26807-65-8

Medically reviewed on Mar 2, 2017


An indoline diuretic and antihypertensive agent; pharmacologically similar to thiazide diuretics.83 500

Uses for Indapamide


Used alone or in combination with other antihypertensive agents for all stages of hypertension.4 19 21 83 a 500

JNC classifies indapamide as a thiazide-like drug with regard to management of hypertension; the drug’s efficacy in hypertensive patients is similar to that of the thiazide diuretics.14 18 21 24 500 501

Thiazide-type diuretics are recommended as one of several preferred agents for the initial management of hypertension; other options include ACE inhibitors, angiotensin II receptor antagonists, and calcium-channel blockers.501 502 503 504 While there may be individual differences with respect to specific outcomes, these antihypertensive drug classes all produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.500 501 502 504 Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).500 501 502 503 504 515

The optimum BP threshold for initiating antihypertensive drug therapy is controversial.501 504 505 506 507 508 515 523 530 Further study needed to determine optimum BP thresholds/goals; individualize treatment decisions.501 503 507 515 526 530

JNC 7 recommends initiation of drug therapy in all patients with uncomplicated hypertension and BP ≥140/90 mm Hg;500 JNC 8 panel recommends SBP threshold of 150 mm Hg for patients ≥60 years of age.501 Although many experts agree that SBP goal of <150 mm Hg may be appropriate for patients ≥80 years of age,502 504 505 530 application of this goal to those ≥60 years of age is controversial, especially for those at higher cardiovascular risk.501 502 505 506 508 511 515

In the past, initial antihypertensive drug therapy was recommended for patients with diabetes mellitus or chronic kidney disease who had BP ≥130/80 mm Hg;500 503 current hypertension management guidelines generally recommend a BP threshold of 140/90 mm Hg for these individuals (same as for the general population of patients without these conditions), although a goal of <130/80 mm Hg may still be considered.501 502 503 504 520 530 535 536 541

Black hypertensive patients generally tend to respond better to monotherapy with thiazide diuretics or calcium-channel blockers than to other antihypertensive drug classes (e.g., ACE inhibitors, angiotensin II receptor antagonists).82 200 500 501 504 However, diminished response to these other drug classes is largely eliminated when administered concomitantly with a thiazide diuretic or calcium-channel blocker.500 504

Thiazide-like diuretics may be preferred in hypertensive patients with osteoporosis. Secondary beneficial effect in hypertensive geriatric patients of reducing the risk of osteoporosis secondary to effect on calcium homeostasis and bone mineralization.

Edema in Heart Failure

Management of edema and salt retention associated with heart failure.21 24 29 39 83

Most experts state that all patients with symptomatic heart failure who have evidence for, or a history of, fluid retention generally should receive diuretic therapy in conjunction with moderate sodium restriction, an agent to inhibit the renin-angiotensin-aldosterone (RAA) system (e.g., ACE inhibitor, angiotensin II receptor antagonist, angiotensin receptor-neprilysin inhibitor [ARNI]), a β-adrenergic blocking agent (β-blocker), and in selected patients, an aldosterone antagonist.524 700 713

Diuretics produce rapid symptomatic benefits, relieving pulmonary and peripheral edema more rapidly (within hours or days) than cardiac glycosides, ACE inhibitors, or β-blockers (in weeks or months).70

Loop diuretics (e.g., bumetanide, ethacrynic acid, furosemide, torsemide) are diuretics of choice for most patients with heart failure.524

Edema in Pregnancy

Diuretics should not be used for routine therapy in pregnant women with mild edema who are otherwise healthy.a

Use of thiazide-like diuretics may be appropriate in the management of edema of pathologic origin during pregnancy when clearly needed; routine use of diuretics in otherwise healthy pregnant women is irrational.21 30

Use of diuretics for the management of edema of physiologic and mechanical origin during pregnancy generally is not warranted.21 30

Dependent edema secondary to restriction of venous return by the expanded uterus should be managed by elevating the lower extremities and/or by wearing support hose; use of diuretics in these pregnant women is inappropriate.21 30

In rare cases when the hypervolemia associated with normal pregnancy results in edema that produces extreme discomfort, a short course of diuretic therapy may provide relief and may be considered when other methods (e.g., decreased sodium intake, increased recumbency) are ineffective.21 30 44

Diuretics will not prevent the development of toxemia, nor is there evidence that diuretics have a beneficial effect on the overall course of established toxemia.21 30

Edema (General)

Management of edema resulting from various causes.24 29 39

No substantial difference in clinical effects or toxicity of comparable thiazide or thiazide-like diuretics, except metolazone may be more effective in edema with renal impairment.a

Indapamide Dosage and Administration


BP Monitoring and Treatment Goals

  • Carefully monitor BP during initial titration or subsequent upward adjustment in dosage.500 501

  • When available, use evidence-based dosing information (i.e., dosages shown in randomized controlled trials to reduce complications of hypertension) to determine target dosages; target dosages usually can be achieved within 2–4 weeks but may take up to several months.501

  • If adequate BP response not achieved with a single antihypertensive agent, add a second drug with demonstrated benefit; if goal BP still not achieved with optimal dosages of 2 antihypertensive agents, add a third drug.501 May maximize dosage of the first drug before adding a second drug, or add a second drug before maximizing dosage of the initial drug.501

  • Consider initiating antihypertensive therapy with a combination of drugs if patient's BP exceeds goal BP by >20/10 mm Hg.500 501 503 504

  • Goal is to achieve and maintain optimal control of BP; individualize specific target BP based on consideration of multiple factors, including patient age and comorbidities, and currently available evidence from clinical studies.500 501 (See Hypertension under Uses.)


Administer orally as a single daily dose in the morning.21 83


Individualize dosage according to individual requirements and response.600

For the management of fluid retention (e.g., edema) associated with heart failure, experts state that diuretics should be administered at a dosage sufficient to achieve optimal volume status and relieve congestion without inducing an excessively rapid reduction in intravascular volume, which could result in hypotension, renal dysfunction, or both.524


Usual Dosage

JNC 8 expert panel recommends initial dosage of 1.25 mg once daily and target dosage of 1.25–2.5 mg once daily based on dosages used in randomized controlled studies.501

Manufacturer recommends initial dosage of 1.25 mg once daily in the morning; if response is inadequate, dosage may be increased at 4-week intervals to 2.5 mg daily and subsequently to 5 mg daily.83

Dosages >5 mg daily do not appear to result in further improvement in BP and increase the risk of hypokalemia.83 (See Hypokalemia under Cautions.)

If adequate response is not achieved with monotherapy, add another antihypertensive agent.501

If concomitant therapy with other antihypertensive agents is required, the usual dose of the other agent may need to be reduced initially by up to 50%; subsequent dosage adjustments should be based on BP response.44 83 Dosage reduction of both drugs may be required.39

If intolerable adverse effects occur, consider dosage reduction; if adverse effects worsen or fail to resolve, may need to discontinue and switch to another antihypertensive drug class.501

Edema in Heart Failure

Initially, 2.5 mg once daily in the morning.83

If response is inadequate after 1 week, dosage may be increased to 5 mg daily given as a single dose in the morning.21 83

Dosages >5 mg daily do not appear to result in further improvement in heart failure and increase the risk of hypokalemia.83 24 29 39 83 (See Hypokalemia under Cautions.)

Edema (General)

Similar dosages to those employed for the management of edema associated with heart failure have been used in the management of edema from other causes.29

Prescribing Limits



Dosages >5 mg daily do not appear to result in further improvement in heart failure or BP and are associated with increased risk of hypokalemia;24 29 39 83 such dosages have been employed only in a limited number of clinical studies.24 29 39 83

Special Populations

Hepatic Impairment

No specific dosage recommendations.83 (See Hepatic Impairment under Cautions.)

Renal Impairment

No specific dosage recommendations.4 24 83 (See Renal Impairment under Cautions.)

Geriatric Patients

No specific dosage recommendations.83 (See Geriatric Use under Cautions.)

Cautions for Indapamide


  • Anuria.21

  • Known hypersensitivity to indapamide or other sulfonamide derivatives.21




Severe hyponatremia (serum sodium concentration <120 mEq/L), accompanied by hypokalemia, occurs rarely.51 52 53 54 55 56 57 58 59 60 61 Do not administer sodium chloride unless the hyponatremia is life threatening or actual sodium depletion is documented.21 If sodium chloride is administered, initially only correct to a state of mild hyponatremia; avoid early overcorrection to normonatremia or hypernatremia (risk of central pontine myelinolysis).52 55 60 62

Risk of hyponatremia appears to be dose related;51 52 53 54 55 56 61 83 risk is greater in patients receiving a daily dosage of 2.5 or 5 mg.83

Possible dilutional hyponatremia; occurs most commonly in patients with edema.21 51 54 Usually asymptomatic and managed by fluid intake restriction (e.g., 500 mL/day)21 and withdrawal of the diuretic.51 54


Hypokalemia occurs commonly.9 21 24 28 47 Increased risk of hypokalemia, especially with brisk diuresis; large dosages (i.e., ≥5 mg daily);21 24 29 39 40 83 inadequate oral electrolyte intake; in presence of severe cirrhosis, hyperaldosteronism, or potassium-losing renal diseases; or during concomitant use of corticosteroids or ACTH.21 24 83

Risk of hypochloremic alkalosis associated with hypokalemia, especially in patients with renal or liver disease; usually mild.21 Specific therapy generally not required.21

Supplemental potassium chloride (including potassium-containing salt substitutes) may be necessary to prevent or treat hypokalemia and/or metabolic alkalosis.21 28 44


Generally, do not use with lithium salts.21 (See Specific Drugs under Interactions.)

Sensitivity Reactions

Dermatologic Reactions

Rash (e.g., erythematous, maculopapular, morbilliform), urticaria, pruritus, and vasculitis reported.21 63 In some cases, rash was accompanied by fever and/or dysuria.63 Rash generally resolves within 2 weeks after drug discontinuance, usually without specific therapy.63 64 May be treated with antihistamines.63

Erythema multiforme and epidermal necrolysis63 reported rarely.c

General Precautions

Fluid and Electrolyte Imbalance

Risk of electrolyte disturbances (e.g., hyponatremia, hypokalemia, hypochloremic alkalosis, hypomagnesemia).21 (See Hyponatremia and also Hypokalemia under Cautions.)

Periodic determinations of serum electrolyte concentrations (particularly potassium, sodium, chloride, and bicarbonate) should be performed and are especially important in patients at increased risk from hypokalemia (e.g., geriatric patients, those with cardiac arrhythmias, receiving concomitant cardiac glycosides, and/or with a history of ventricular arrhythmias),21 24 39 and those with diabetes mellitus, vomiting, diarrhea, parenteral fluid therapy, or expectations of other electrolyte imbalance (e.g., heart failure, renal disease, cirrhosis, restricted sodium intake, advanced age).21 83

Observe carefully for manifestations of fluid and electrolyte depletion (e.g., dryness of mouth, thirst, weakness, fatigue, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, GI disturbance).21 83 Measures to maintain normal serum concentrations should be instituted if necessary.21 83


Risk of hyperuricemia, especially in patients with a history of gout, family predisposition to gout, or chronic renal failure.4 10 12 17 25 28 29 39 47 Usually asymptomatic and rarely leads to clinical gout.19 21 24 28 29 39

Generally avoid or use with caution in hypertensive patients with a history of gout or elevated uric acid concentrations.500 502

Monitor serum uric acid concentrations periodically.83 Hyperuricemia and gout may be treated with a uricosuric agent.28 39

Endocrine Effects

Risk of increased blood glucose, hyperglycemia, glycosuria, and impaired glucose tolerance;15 21 24 28 precipitation of diabetes mellitus rarely reported in patients with a history of impaired glucose tolerance (latent diabetes).21

Monitor blood glucose concentrations periodically, especially in patients with known or suspected (e.g., marginally impaired glucose tolerance) diabetes mellitus.21


May decrease calcium urinary excretion; slight intermittent serum calcium increases reported;83 clinically important changes in serum total or ionic calcium concentrations have not been reported.20 21 24

Use with caution in patients with hyperparathyroidism or thyroid disorders.21 Discontinue prior to performing parathyroid tests.21 83

Lupus Erythematosus

Possible exacerbation or activation of systemic lupus erythematosus.21 83


Antihypertensive effect may be enhanced after sympathectomy.21

Fetal/Neonatal Morbidity

Diuretics cross the placental barrier and appear in cord blood.83 Use with caution; possibility of fetal or neonatal jaundice, thrombocytopenia, and other adverse effects reported in adults.83

Specific Populations


Category B.83

Diuretics are considered second-line agents for control of chronic hypertension in pregnant women;142 500 if initiation of antihypertensive therapy is necessary during pregnancy, other antihypertensives (i.e., methyldopa, nifedipine, labetalol) are preferred.142 540

Diuretics are not recommended for prevention or management of gestational hypertension or preeclampsia.141 539 540


Not known whether distributed into human milk.83 Manufacturer states to discontinue nursing or the drug;83 however, considered to be compatible with breast-feeding.141

Pediatric Use

Safety and efficacy not established.83

Geriatric Use

Use with caution in geriatric patients, especially females who are underweight; increased risk of dilutional hyponatremia.51 52 53 54 55 56 61 (See Hyponatremia under Cautions.)

Increased risk of hypokalemia; close monitoring recommended.21 24 39 (See Hypokalemia under Cautions.)

Hepatic Impairment

Use with caution in hepatic impairment or progressive liver disease (particularly with associated potassium deficiency); electrolyte and fluid imbalance may precipitate hepatic coma.21 83

Increased risk of hypochloremic alkalosis associated with hypokalemia.21

Renal Impairment

Use with caution in patients with severe renal disease; reduced plasma volume may exacerbate or precipitate azotemia.4 21 83

Increased risk of hypochloremic alkalosis associated with hypokalemia.21

Risk of hyperuricemia in patients with chronic renal failure.4 10 12 17 25 28 29 39 47

Diuretic effect declines with decreasing renal function.4 21 83

Evaluate renal function (e.g., BUN, Scr) periodically.21

Consider interruption or discontinuance if progressive renal impairment (rising nonprotein nitrogen, BUN, or Scr) occurs.21 83

Common Adverse Effects

Hypokalemia,9 21 24 28 47 headache,3 21 24 28 dizziness,3 21 24 28 29 fatigue,3 21 24 weakness,21 29 lethargy,21 tiredness,21 malaise,21 muscle cramps or spasm,3 21 24 29 numbness of the extremities,21 nervousness,21 24 tension, anxiety, irritability, agitation.21 83

Interactions for Indapamide

Specific Drugs




Antihypertensive agents

Additive hypotensive effect;21 44 83 possible potentiation of postural hypotension21

Usually used to therapeutic advantage21 83

If concomitant therapy with other antihypertensive agents is required, dose of the other agent may need to be reduced initially by up to 50%; subsequent dosage adjustments should be based on BP response;44 83 dosage reduction of both drugs may be required39

Monitor for possible postural hypotension21

Digitalis glycosides

Possible electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) may predispose to digitalis toxicity; possibly fatal cardiac arrhythmias21

Monitor electrolytes; correct hypokalemia21

Diuretics, potassium-sparing (e.g., amiloride, triamterene)

Concomitant therapy not fully evaluated40

Safety and efficacy of concurrent use for the prevention of hypokalemia have not been fully determined40


Possible precipitation of diabetes mellitus21 and altered insulin requirements83 (see Endocrine Effects under Cautions)

Monitor blood glucose concentrations periodically, especially in patients with known or suspected (e.g., marginally impaired glucose tolerance) diabetes mellitus21


Reduced renal clearance of lithium and increased risk of lithium toxicity21 23 24

Concomitant use generally contraindicated21

If concomitant therapy is necessary, monitor serum lithium concentrations and reduce lithium dosage by about 50%23 35

Potassium-depleting drugs (e.g., corticosteroids, corticotropin, amphotericin B)

Additive hypokalemic effects21

Monitor electrolytes; correct hypokalemia83

Vasopressors (e.g., norepinephrine, phenylephrine)

Possible decrease in arterial responsiveness to vasopressors21 24 27 39

Unlikely to be clinically important21

Indapamide Pharmacokinetics



Rapidly and completely absorbed following oral administration, with peak plasma concentration usually attained within 2–2.5 hours.16 20 21 24 39 83


Food or antacids do not appear to affect absorption.20 24



Lipophilic; widely distributed into most tissues.16 20 24

Not known whether indapamide crosses the placenta or is distributed into milk.21 40

Preferentially and reversibly distributes into erythrocytes;20 21 25 39 83 whole blood/plasma ratio is about 6 during peak concentration20 21 24 and about 3.5 eight hours after administration.21 83

Competitively and reversibly binds to carbonic anhydrase in erythrocytes, but does not appreciably inhibit the enzyme.24 39

Plasma Protein Binding

Approximately 71–79%.20 21 24 39 83



Extensively metabolized in the liver, principally to glucuronide and sulfate conjugates.16 20 21 24 39

Elimination Route

Excreted in urine (70%) mainly as metabolites and in feces (16–23%), probably including biliary elimination.20 21 25 39 83


Biphasic; terminal half-life is approximately 14–26 hours.16 20 21 24 39 83

Special Populations

Half-life is not prolonged in patients with impaired renal function.4 20 24

Not removed from circulation by hemodialysis.4





Tight, light-resistant containers at 20–25°C; avoid excessive heat.600


  • A sulfonamide diuretic; 12 24 pharmacologically and structurally related to thiazide diuretics.6 8 12 14 18 21 24 25 26 38 39 42

  • Enhances excretion of sodium, chloride, and water by interfering with the transport of sodium ions across the renal tubular epithelium.12 20 24 25 26 39

  • Exact tubular mechanism(s) of action is not known;25 principal site of action appears to be the cortical diluting segment of the distal convoluted tubules of the nephron.20 21 25 26 39

  • Appears to indirectly increase potassium excretion by increasing the sodium load at the distal renal tubular site of sodium-potassium exchange.20 24

  • Increases proximal calcium reabsorption and does not inhibit distal calcium reabsorption in the renal tubules.20 21 24 25

  • Decreases free water clearance during hydration20 24 but not during dehydration.20

  • Decreases urinary uric acid excretion.24 25 28 39

  • No substantial effect on GFR or renal blood flow.4 20 21 24

  • May increase plasma renin activity and urinary aldosterone secretion.2 24 27

  • Hypotensive activity in hypertensive patients;19 20 21 24 28 also augments the action of other hypotensive agents.21

  • Precise mechanism of hypotensive action has not been determined, but postulated that diuretics lower BP mainly by reducing plasma and extracellular fluid volume41 44 and by decreasing peripheral vascular resistance possibly secondary to sodium depletion43 and/or vascular autoregulatory feedback mechanisms;41 however, part of the hypotensive effect of indapamide may be caused by direct arteriolar dilation.5 6 21 24 25 27 39

  • Reduces total peripheral resistance.20 21 24

  • Usually no effect on cardiac output20 21 or left ventricular function12 13 in hypertensive patients.21 24

Advice to Patients

  • Importance of informing patients of the signs and symptoms of electrolyte imbalance and instructing them to contact their clinician if dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, oliguria, hypotension, tachycardia, GI disturbance, or muscle pains or cramps occur.21

  • Importance of informing patients with diabetes mellitus that blood glucose and urine glucose concentrations may increase.83

  • Advise hypertensive patients of importance of continuing lifestyle/behavioral modifications that include weight reduction (for those who are overweight or obese), dietary changes to include foods that are rich in potassium and calcium and moderately restricted in sodium (adoption of the Dietary Approaches to Stop Hypertension [DASH] eating plan), increased physical activity, smoking cessation, and moderation of alcohol intake.500

  • Advise that lifestyle/behavioral modifications reduce BP, enhance antihypertensive drug efficacy, and decrease cardiovascular risk and remain an indispensable part of the management of hypertension.500

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.83

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.83

  • Importance of informing patients of other important precautionary information. (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



Dosage Forms


Brand Names



Tablets, film-coated

1.25 mg*

Indapamide Tablets

2.5 mg*

Indapamide Tablets

AHFS DI Essentials. © Copyright 2019, Selected Revisions March 2, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


2. Noveck RJ, Quiroz A, Giles T et al. Hemodynamic effects of a new antihypertensive-diuretic, indapamide in healthy male volunteers. Clin Pharmacol Ther. 1982; 31:257.

3. Passeron J, Pauly N, Desprat J. International multicentre study of indapamide in the treatment of essential arterial hypertension. Postgrad Med J. 1981; 57(Suppl. 2):57-9.

4. Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J. 1983; 106:237-44.

5. Mironneau J, Gargouil Y. Action of indapamide on excitation-contraction coupling in vascular smooth muscle. Eur J Pharmacol. 1979; 57:57-67.

6. Mironneau J, Savineau J, Mironneau C. Compared effects of indapamide, hydrochlorothiazide, and chlorthalidone on electrical and mechanical actions in vascular smooth muscle. Eur J Pharmacol. 1981; 75:109-13.

7. Guidi G, Giuntoli F, Saba G et al. Clinical investigation on efficacy of indapamide as an antihypertensive agent. Curr Ther Res. 1982; 31:601-7.

8. Chalmers JP, Bune AJC, Graham JR et al. Comparison of indapamide with thiazide diuretics in patients with essential hypertension. Med J Aust. 1981; 2:100-1.

9. Wheeley MSG, Bolton JC, Campbell DB. Indapamide in hypertension: a study in general practice of new or previously poorly controlled patients. Pharmatherapeutica. 1982; 3:143-51.

10. Weidman P, Meier A, Mordasini R et al. Diuretics, indapamide and serum lipoproteins. Postgrad Med J. 1981; 57(Suppl. 2):73.

11. Haiat R, Lellouch A, Lanfranchi J et al. Continuous electrocardiographic recording (Holter method) during indapamide treatment: a study of 40 cases. Postgrad Med J. 1981; 57(Suppl. 2):68-9.

12. Horgan JH, O’Donovan A, Teo KK. Echocardiographic evaluation of left ventricular function in patients showing an antihypertensive and biochemical response to indapamide. Postgrad Med J. 1981; 57(Suppl. 2):64-7.

13. Dunn FG, Hillis WS, Tweddel A et al. Non-invasive cardiovascular assessment of indapamide in patients with essential hypertension. Postgrad Med J. 1981; 57(Suppl. 2):19-22.

14. Zacharis FJ. A comparative study of the efficacy of indapamide and bendrofluazide given in combination with atenolol. Postgrad Med J. 1981; 57(Suppl. 2):51-2.

15. Roux P, Courtois H. Blood sugar regulation during treatment with indapamide in hypertensive diabetics. Postgrad Med J. 1981; 57(Suppl. 2):70-2.

16. Grebow PE, Trectman JA, Barry EP et al. Pharmacokinetics and bioavailability of indapamide—a new antihypertensive drug. Eur J Clin Pharmacol. 1982; 22:295-9.

17. Van Hee W, Thomas J, Brems H. Indapamide in the treatment of essential arterial hypertension in the elderly. Postgrad Med J. 1981; 57(Suppl. 2):29-33.

18. James I, Griffith D, Davis J et al. Comparison of the antihypertensive effects of indapamide and cyclopenthiazide. Postgrad Med J. 1981; 57(Suppl. 2):39-41.

19. Morledge JH. Clinical efficacy and safety of indapamide in essential hypertension. Am Heart J. 1983; 106:229-32.

20. Caruso FS, Szabadi RR, Vukovich RA. Pharmacokinetics and clinical pharmacology of indapamide. Am Heart J. 1983; 106:212-20.

21. Rorer Pharmaceuticals. Lozol (indapamide) tablets prescribing information. Fort Washington, PA; 1990 Jul.

22. Kradjan WA, Koda-Kimble MA. Congestive heart failure. In: Katcher BS, Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 3rd ed. San Francisco: Applied Therapeutics, Inc.; 1983:176.

23. Coleman JH, Johnston JA. Affective disorders. In: Katcher BS, Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 3rd ed. San Francisco: Applied Therapeutics, Inc.; 1983:1035-6.

24. Chaffman M, Heel RC, Brogden TM et al. Indapamide, a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1984; 28:189-35.

25. Materson BJ. Insights into intrarenal sites and mechanisms of action of diuretic agents. Am Heart J. 1983; 106:188-208.

26. Pruss T, Wolf PS. Preclinical studies of indapamide, a new 2-methylindoline antihypertensive agent. Am Heart J. 1983; 106:208-11.

27. Noveck RJ, McMahon FG, Quiros A et al. Extrarenal contributions to indapamide’s antihypertensive mechanism of action. Am Heart J. 1983; 106:221-9.

28. Beling S, Vukovich RA, Neiss ES et al. Long-term experience with indapamide. Am Heart J. 1983; 106:258-62.

29. Slotkoff L. Clinical efficacy and safety of indapamide in the treatment of edema. Am Heart J. 1983; 106:233-7.

30. US Food and Drug Administration. Limited usefulness of diuretics in pregnancy. FDA Drug Bull. 1977; 7:7.

31. Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J. 1983; 106:245-51.

32. Grimm RH, Leon AS, Hunninghake DB et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med. 1981; 94:7-11.

33. Goldman AI, Steele BW, Schnaper HW et al. Serum lipoprotein levels during chlorthalidone therapy, a Veterans Administration—National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension. JAMA. 1980; 244:1691-5.

34. Helgeland A, Leren P, Foss OP et al. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. Am J Med. 1984; 76:802-5.

35. Lott RS. Lithium interactions. Drug Interact Newsl. 1983; 3:17-22.

36. Rowe JW, Tobin JD, Rosa RM et al. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism. 1980; 29:498-502.

37. Helderman JH, Elahi D, Anderson DK et al. Prevention of glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983; 32:106-11.

38. Windholz M, ed. The Merck index. 10th ed. Rahway, NJ: Merck & Co., Inc.: 1983.

39. Mroczek WJ. Indapamide: clinical pharmacology, therapeutic efficacy in hypertension, and adverse effects. Pharmacotherapy. 1983; 3:61-7.

40. Hansen KB (Revlon Health Care Group Ethical Products Division, Tarrytown, NY): Personal communication; 1984 Oct 1.

41. Freis ED. How diuretics lower blood pressure. Am Heart J. 1983; 106:185-7.

42. Mudge GH. Drugs affecting renal function and electrolyte metabolism. In: Gilman AG, Goodman L, Gilman A, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Company; 1980:899-903.

43. Blaschke TF, Melmon KL. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Goodman L, Gilman A, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Company; 1980:803-4.

44. Reviewers’ comments (personal observations); 1984 Oct.

45. The United States Pharmacopeial Convention, Inc. Indapamide tablets. Pharmacopeial Forum. 1989; 15:5475-7.

46. Scalabrino A, Galeone F, Giuntoli F et al. Clinical investigation on long-term effects of indapamide in patients with essential hypertension. Curr Ther Res. 1984; 35:17-22.

47. Weidman P, Bianchetti MG, Mordasini R. Effects of indapamide and various diuretics alone or combined with beta-blockers on serum lipoproteins. Curr Med Res Opin. 1983 (Suppl. 3); 8:123-34.

49. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part II: alternating monotherapy is the preferred treatment. Pharmacotherapy. 1985; 5:195-200.

50. Bauer JH. Stepped-care approach to the treatment of hypertension: is it obsolete? (unpublished observations)

51. Ayus JC. Diuretic-induced hyponatremia. Arch Intern Med. 1986; 146:1295.

52. Ashouri OS. Severe diuretic-induced hyponatremia in the elderly: a series of eight patients. Arch Intern Med. 1986; 146:1355-7.

53. Sonnenblick M, Algur N, Rosin A. Thiazide-induced hyponatremia and vasopressin release. Ann Intern Med. 1989; 110:751.

54. Friedman E, Shadel M, Halkin H et al. Thiazide-induced hyponatremia: reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med. 1989; 110:24-30.

55. Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. Ann Intern Med. 1987; 107:656-64.

56. Bain PG, Egner W, Walker PR. Thiazide-induced dilutional hyponatremia masquerading as subarachnoid haemorrhage. Lancet. 1986; 2:634.

57. Booker JA. Severe symptomatic hyponatremia in elderly outpatients: the role of thiazide therapy and stress. J Am Geriatr Soc. 1984; 32:108-13.

58. Johnson JE, Wright LF. Thiazide-induced hyponatremia. South Med J. 1983; 76:1363-7.

59. Kone B, Gimenez L, Watson AJ. Thiazide-induced hyponatremia. South Med J. 1986; 79:1456-7.

60. Mozes B, Pines A, Werner D et al. Thiazide-induced hyponatremia: an unusual neurologic course. South Med J. 1986; 79:629-31.

61. Oles KS, Denham JW. Hyponatremia induced by thiazide-like diuretics in the elderly. South Med J. 1984; 77:1314-5.

62. Ayus JC, Krothapalli RK, Arieff Al. Changing concepts in treatment of severe symptomatic hyponatremia: rapid correction and possible relation to central pontine myelinolysis. Am J Med. 1985; 78(6 Part 1):897-902.

63. Stricker BHC, Biriell C. Skin reactions and fever with indapamide. BMJ. 1987; 295:1313-4.

64. Kandela D, Guez D. Skin reactions and fever with indapamide. BMJ. 1988; 296:573.

67. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80.

68. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45.

69. Whelton PK, Appel LJ, Espeland MA et al. or the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46.

70. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9-38A.

71. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988; 259:539-44.

72. Richardson A, Bayliss J, Scriven AJ et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987; 2:709-11.

73. Sherman LG, Liang CS, Baumgardner S et al. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986; 40:587-94.

74. Patterson JH, Adams KF Jr, Applefeld MM et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994; 14:514-21.

75. Wilson JR, Reichek N, Dunkman WB et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70:234-9.

76. Parker JO. The effects of oral ibopamine in patients with mild heart failure—a double blind placebo controlled comparison to furosemide. Int J Cardiol. 1993; 40:221-7.

77. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4.

78. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20.

79. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61.

80. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from website.

81. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42.

82. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97.

83. Aventis Pharmaceuticals. Lozol (indapamide) tablets prescribing information. Bridgewater, NJ; 2002 Dec.

85. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet. 2000; 356:1955-64.

86. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002; 4:393-404.

87. Black HR, Elliott WJ, Neaton JD et al. Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension. 2001; 37:12-18.

88. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289:2073-2082.

89. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE). Lancet. 2002; 359:995-1003.

90. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342:145-153.

91. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-41.

92. Wing LMH, Reid CM, Ryan P, et al, for Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348:583-92.

93. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-2.

94. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol. 2001; 38:2101-2113.

141. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:255-8.

142. ACOG task force on hypertension in pregnancy: hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.

200. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

217. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

218. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002; 39(Suppl 2):S1-246.

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20.

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357.

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85.

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26.

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503.

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4.

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6.

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8.

511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27.

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88.

520. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014; 37 Suppl 1:S14-80.

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :.

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8.

535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13.

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

539. Churchill D, Beevers GD, Meher S et al. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev. 2007; :CD004451.

540. Magee LA, Pels A, Helewa M et al., for the Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014; 4:105-45.

541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701.

600. Mylan Pharmaceuticals. Indapamide tablets prescribing information. Morgantown, WV; 2010 Jan.

700. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.

713. Gupta D, Georgiopoulou VV, Kalogeropoulos AP et al. Dietary sodium intake in heart failure. Circulation. 2012; 126:479-85.

723. Hummel SL, Konerman MC. Dietary Sodium Restriction in Heart Failure: A Recommendation Worth its Salt?. JACC Heart Fail. 2016; 4:36-8.

724. Yancy CW. The Uncertainty of Sodium Restriction in Heart Failure: We Can Do Better Than This. JACC Heart Fail. 2016; 4:39-41.

a. AHFS drug information 2017. McEvoy GK, ed. Thiazides general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2017: .

c. AHFS drug information 2015. McEvoy GK, ed. Indapamide. Bethesda, MD: American Society of Health-System Pharmacists; 2015: .